NCT07003191Active, not recruiting
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
Multicenter, Prospective, Observational Study of Metformin Hydrochloride and Empagliflozin Tablets (Enshuangping) in the Treatment of Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 4 Jun 2025
Brief summary (registry, in English)
The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2600 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 2 Aug 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07003191
What you commit to
- Study type: Observational
- Planned participants: 2600
- From 2 Aug 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A history of severe allergy to empagliflozin, metformin, or any excipient in this product;
Lab values
- Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73 m²), end-stage renal disease, or dialysis;
Other
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis;
- Currently or within the past month, participation in any other clinical trials;
- Judged by the investigator to be unsuitable for participation in this study.
Who the study is looking for
- Age ≥ 18 years, gender unrestricted;
- Clinically diagnosed with type 2 diabetes;
- First-time treatment with metformin and empagliflozin tablets;
- HbA1c test results within 2 weeks prior to enrollment (rapid fingertip test results are acceptable);
- Voluntary participation in the study and signing of informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Endocrinology Department, The First Affiliated Hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.